Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23NO.C4H6O6.2H2O |
Molecular Weight | 443.488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CCCC[C@@]13CCN(C)[C@@H]2CC4=C3C=C(O)C=C4
InChI
InChIKey=UMZNDVASJKIQCB-QLFXFZCRSA-N
InChI=1S/C17H23NO.C4H6O6.2H2O/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17;5-1(3(7)8)2(6)4(9)10;;/h5-6,11,14,16,19H,2-4,7-10H2,1H3;1-2,5-6H,(H,7,8)(H,9,10);2*1H2/t14-,16+,17+;1-,2-;;/m01../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C17H23NO |
Molecular Weight | 257.3706 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic
is appropriate. It is a potent synthetic opioid mu-receptor agonist similar in action to morphine. Like other opioid
mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission
and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to
morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression
similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists,
levorphanol produces euphoria or has a positive effect on mood in many individuals.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
0.21 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
4.2 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
2.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Levorphanol Tartrate Approved UseLevorphanol Tartrate Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date-5.3585281E11 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 11.5 uM] | ||||
yes [IC50 >50 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. | 1981 |
|
Prostaglandin hyperalgesia, V: a peripheral analgesic receptor for opiates. | 1982 Jan |
|
Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine. | 1984 |
|
Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. | 1984 Jun 25 |
|
Baclofen-induced catatonia. | 1986 Dec |
|
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995 Sep |
|
Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor. | 2001 Aug |
|
The safety of dextromethorphan in pregnancy : results of a controlled study. | 2001 Feb |
|
Clinical pharmacology of opioids for pain. | 2002 Jul-Aug |
|
Sensitivity to the effects of opioids in rats with free access to exercise wheels: mu-opioid tolerance and physical dependence. | 2003 Aug |
|
Opioids and chronic neuropathic pain. | 2003 Mar 27 |
|
Oral opioid therapy for chronic peripheral and central neuropathic pain. | 2003 Mar 27 |
|
The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. | 2003 Nov |
|
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. | 2004 Jan 1 |
|
Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. | 2005 Oct |
|
Levorphanol revisited. | 2007 Dec |
|
Current aproach to cancer pain management: Availability and implications of different treatment options. | 2007 Jun |
|
Levorphanol: the forgotten opioid. | 2007 Mar |
|
High-affinity carbamate analogues of morphinan at opioid receptors. | 2007 Mar 15 |
|
Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. | 2007 May 31 |
|
Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A. | 2007 Oct 26 |
|
Opiates and elderly: use and side effects. | 2008 |
|
A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. | 2009 Jun 30 |
|
Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. | 2010 Jan |
|
Acute pain management in children. | 2010 Jul 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/levorphanol.html
Usual Adult Dose for Light Sedation
Premedication for Anesthesia:
1 to 2 mg IM or subcutaneously, administered 60 to 90 minutes before surgery. Older or debilitated patients usually require less drug. Two mg of levorphanol is approximately equivalent to 10 to 15 mg of morphine or 100 mg of meperidine.
Usual Adult Dose for Pain
IV: 1 mg every 3 to 6 hours as needed.
IM or subcutaneous: 1 to 2 mg every 6 to 8 hours as needed.
Oral: 2 mg every 6 to 8 hours as needed.
May be increased to 3 mg every 6 to 8 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7284815
Levorphanol (5-100 uM), consistently depressed the responses evoked by the putative inhibitory amino acid neurotransmitters glycine and beta-alanine but not GABA in cultured mouse spinal cord neurons.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:03:24 UTC 2023
by
admin
on
Wed Jul 05 23:03:24 UTC 2023
|
Record UNII |
04WQU6T9QI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1506
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5985-38-6
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
100000086127
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
M6794
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID30975252
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
DBSALT000935
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
04WQU6T9QI
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
6700-40-9
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
SUPERSEDED | |||
|
04WQU6T9QI
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
153973
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
5985-51-3
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
SUPERSEDED | |||
|
5462348
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
C47586
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
1364007
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
SUB02914MIG
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL592
Created by
admin on Wed Jul 05 23:03:25 UTC 2023 , Edited by admin on Wed Jul 05 23:03:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |